Mills P, Ng J, Auer D
Vet Res Commun. 1997; 21(5):361-8.
PMID: 9232780
DOI: 10.1023/a:1005816422279.
Desai N, sheth U, Mucklow J, Fraser H, Bulpitt C, Jones S
Br J Clin Pharmacol. 1980; 9(4):387-94.
PMID: 7378255
PMC: 1429972.
DOI: 10.1111/j.1365-2125.1980.tb01066.x.
Tawara K, Kawashima K, Ishikawa H, Yamamoto K, Saito K, Ebihara A
Eur J Clin Pharmacol. 1981; 19(3):197-203.
PMID: 6894282
DOI: 10.1007/BF00561949.
Terao N, Shen D
J Pharmacokinet Biopharm. 1984; 12(5):479-93.
PMID: 6520744
DOI: 10.1007/BF01060127.
Dorian P, Sellers E, KAPLAN H, Carruthers G, Hamilton C, Khouw V
Eur J Clin Pharmacol. 1984; 27(2):209-15.
PMID: 6499899
DOI: 10.1007/BF00544047.
Pharmacokinetic drug interactions with propranolol.
Wood A, Feely J
Clin Pharmacokinet. 1983; 8(3):253-62.
PMID: 6342901
DOI: 10.2165/00003088-198308030-00004.
Influence of thyroid dysfunction on drug pharmacokinetics.
Shenfield G
Clin Pharmacokinet. 1981; 6(4):275-97.
PMID: 6166422
DOI: 10.2165/00003088-198106040-00003.
Influence of food on the intravenous and oral dose kinetics of propranolol in the dog.
Bai S, Walle U, Walle T
J Pharmacokinet Biopharm. 1985; 13(3):229-41.
PMID: 4087163
DOI: 10.1007/BF01065654.
Importance of drug enantiomers in clinical pharmacology.
Williams K, Lee E
Drugs. 1985; 30(4):333-54.
PMID: 3905334
DOI: 10.2165/00003495-198530040-00003.
Clinical applicability of current pharmacokinetic models: splanchnic elimination of 5-fluorouracil in cancer patients.
Robinson P, Bass L, Pond S, Roberts M, Wagner J
J Pharmacokinet Biopharm. 1988; 16(3):229-49.
PMID: 3221324
DOI: 10.1007/BF01062135.
Axial tissue diffusion can account for the disparity between current models of hepatic elimination for lipophilic drugs.
Rivory L, Roberts M, Pond S
J Pharmacokinet Biopharm. 1992; 20(1):19-61.
PMID: 1588503
DOI: 10.1007/BF01143185.
The effect of cirrhosis on the disposition and elimination of clindamycin.
Avant G, Schenker S, ALFORD R
Am J Dig Dis. 1975; 20(3):223-30.
PMID: 1168411
DOI: 10.1007/BF01070725.
The effects of age and liver disease on the disposition and elimination of diazepam in adult man.
Klotz U, Avant G, Hoyumpa A, Schenker S, Wilkinson G
J Clin Invest. 1975; 55(2):347-59.
PMID: 1127104
PMC: 301753.
DOI: 10.1172/JCI107938.
Propranolol disposition in chronic liver disease: a physiological approach.
Branch R, SHAND D
Clin Pharmacokinet. 1976; 1(4):264-79.
PMID: 797499
DOI: 10.2165/00003088-197601040-00002.
The effect of ageing on the hepatic clearance of propranolol.
Castleden C, George C
Br J Clin Pharmacol. 1979; 7(1):49-54.
PMID: 760742
PMC: 1429596.
DOI: 10.1111/j.1365-2125.1979.tb00896.x.
Hepatic clearance of drugs. III. Additional experimental evidence supporting the "well-stirred" model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ....
Pang K, Rowland M
J Pharmacokinet Biopharm. 1977; 5(6):681-99.
PMID: 599413
DOI: 10.1007/BF01059690.
Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred" model over the "parallel tube" model using lidocaine in the perfused rat liver in situ preparation.
Pang K, Rowland M
J Pharmacokinet Biopharm. 1977; 5(6):655-80.
PMID: 599412
DOI: 10.1007/BF01059689.
Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.
Pang K, Rowland M
J Pharmacokinet Biopharm. 1977; 5(6):625-53.
PMID: 599411
DOI: 10.1007/BF01059688.
Drug prescribing in hepatobiliary disease.
Roberts R, Desmond P, Schenker S
Drugs. 1979; 17(3):198-212.
PMID: 378647
DOI: 10.2165/00003495-197917030-00005.
Protein binding and kinetics of drugs in liver diseases.
Blaschke T
Clin Pharmacokinet. 1977; 2(1):32-44.
PMID: 322909
DOI: 10.2165/00003088-197702010-00003.
